文献速递临床试验与 GCP基础与转化研究

加速间歇性θ爆发刺激促进亚急性卒中上肢恢复(ATLAS):多中心随机对照试验方案

Accelerated intermittent theta burst stimulation (iTBS) for the upper limb recovery after subacute stroke (ATLAS): study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2026-07-24

ATLAS是一项前瞻性、单盲、多中心随机对照试验,计划从11个城市13家医院招募240例亚急性卒中患者,随机分为加速iTBS组与低频重复经颅磁刺激组,两组均每周治疗5天、连续3周并联合常规康复。主要结局为治疗3周后FMA-UE评分,旨在比较加速iTBS与标准方案对上肢恢复及整体功能的影响。

要点

  • ATLAS首次在多中心大样本中直接比较加速iTBS与标准低频rTMS对亚急性卒中上肢恢复的疗效。
  • 两组均每周治疗5天、连续3周,并联合物理因子、治疗性运动、作业治疗等常规康复。
  • 主要结局为治疗3周后FMA-UE评分,次要结局涵盖上肢功能、日常生活活动、疾病严重度及神经生理指标。

核心结论

  • ATLAS试验旨在填补加速iTBS促进亚急性卒中上肢恢复的高质量证据空白,并推动更高效iTBS治疗策略的临床转化。

研究设计与样本

  • 前瞻性、单盲、多中心随机对照试验,计划从11个城市13家医院招募240例亚急性卒中患者。
  • 参与者随机分配至加速iTBS组或低频重复经颅磁刺激(LF-rTMS)组,两组均每周治疗5天、连续3周,并联合常规康复治疗。

关键数值与推荐

  • 主要结局为治疗3周后上肢Fugl-Meyer评估(FMA-UE)评分。
  • 次要结局包括上肢功能、日常生活活动、临床疾病严重度及rTMS评估的神经生理指标,于干预后和3周随访时评估。
  • 试验注册于中国临床试验注册中心(ChiCTR2500110766),注册日期2025年10月20日。

临床怎么用

  • 若加速iTBS优于标准LF-rTMS,可为亚急性卒中上肢康复提供更高效的治疗方案并促进临床推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke is the second leading cause of death globally, with residual upper limb dysfunction being a major contributor to its high disability rate. Currently, there remains a lack of effective rehabilitation approaches to substantially improve upper limb dysfunction. While transcranial magnetic stimulation (TMS) has shown potential in promoting functional reorganization in stroke patients, more effective treatment protocols are still under exploration. In recent years, numerous clinical evidence has indicated that intermittent theta burst stimulation (iTBS) may offer a more efficient pathway for the upper limb recovery after stroke. A few studies have employed accelerated iTBS protocols, preliminarily confirming its safety and efficacy, yet large-sample comparative studies against the standard protocol are lacking. This ATLAS trial aims to compare the effects of accelerated iTBS versus a standard TMS protocol on upper limb recovery and overall functional outcomes in patients with subacute stroke. METHODS: This is a prospective, single-blind, multicenter, randomized controlled clinical trial. A total of 240 patients in the subacute phase of stroke will be recruited from 13 hospitals across 11 cities. Participants will be randomly allocated to either an iTBS group or a low-frequency repetitive TMS (LF-rTMS) group. Both groups will receive treatment 5 days per week for three consecutive weeks. In addition, all participants will receive standard conventional rehabilitation therapies, including physical agent modalities, therapeutic exercise, occupational therapy, and other commonly used clinical rehabilitation approaches. The primary outcome is the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) evaluated after 3 weeks of treatment. Secondary outcomes include measures of upper limb function, activities of daily living, clinical disease severity, and neurophysiological indicators assessed by rTMS, evaluated at both post-intervention and after a 3-week follow-up period. DISCUSSION: ATLAS trial is the first multicenter randomized controlled trial to apply an accelerated iTBS protocol to a large cohort of patients with subacute stroke and compare it directly with a standard stimulation protocol. The findings are expected to address the current gap in high-quality evidence regarding the efficacy of accelerated iTBS on upper limb recovery after stroke, thereby promoting the broader clinical adoption of more efficient iTBS-based therapeutic strategies. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2500110766). Registered on Oct 20, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang H, Shu T, Duan C, et al. Accelerated intermittent theta burst stimulation (iTBS) for the upper limb recovery after subacute stroke (ATLAS): study protocol for a multicenter randomized controlled trial. Trials. 2026. PMID: 42907915. doi:10.1186/s13063-026-09857-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。